House dust mite-specific Immunoglobulin E (HDM-sIgE)

House dust mite-specific Immunoglobulin E (HDM-sIgE) is a specialized antibody class that mediates Type I hypersensitivity reactions to allergens from mites such as Dermatophagoides pteronyssinus [1, 2]. It exists in two critical states: as a membrane-bound receptor on IgE-switched B cells and bound to high-affinity FcεRI receptors on the surface of effector cells like mast cells and basophils [5, 10, 12]. Upon exposure to house dust mite allergens, the cross-linking of these bound IgE molecules triggers the immediate release of inflammatory mediators, including histamine and leukotrienes, which drive the symptoms of allergic asthma and rhinitis [5, 10]. Therapeutic strategies targeting this molecule include monoclonal antibodies like omalizumab, which neutralize free IgE to prevent its binding to effector cells, and allergen-specific immunotherapy (AIT), which aims to desensitize the immune system [7, 15]. AIT works by inducing regulatory T cells and protective IgG4 antibodies that compete with HDM-sIgE for allergen binding [1, 4, 8]. Monitoring the levels of HDM-sIgE and its ratio to total IgE serves as a vital biomarker for diagnosing sensitization and evaluating the success of disease-modifying treatments [2, 14].

Other names

HDM-sIgE [12]House dust mite-specific IgE [4]Mite-specific IgE [4]Reaginic antibody [5, 10]

Neutralization of free IgE to prevent binding to FcεRI [7, 10]; induction of allergen-specific IgG4 'blocking' antibodies [1, 4, 8]; downregulation of FcεRI expression on effector cells [14]; and modulation of T-cell responses toward a Th1/Treg profile [1, 5, 14].